FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295431110> ?p ?o ?g. }

• W4295431110 endingPage "630" @default.
• W4295431110 startingPage "627" @default.
• W4295431110 abstract "Vaccination has been an effective public health measure in the coronavirus disease-19 (COVID-19) pandemic.1, 2 However, since the sudden death of a previously healthy recipient diagnosed with de novo immune thrombocytopenia (ITP) after vaccination was reported, public alarm has been heightened.3 Although it is difficult to precisely assess whether post-vaccination thrombocytopenia is vaccine-induced or incidental, further, the association is chronological and not necessarily causal, ITP can develop after COVID-19 vaccination.4-7 However, the humoral response in such patients is unknown and it must be of great concern to both patients and their physicians. Furthermore, a recent study reported that active treatment with corticosteroids reduced immunogenicity in patients with autoimmune cytopenias including ITP.8 Hence, we considered the possibility that corticosteroids treatment for patients with post-COVID-19 vaccine ITP exacerbation might affect the vaccine response. Therefore, in this prospective observation study, we investigated the antibody titres against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in patients with de novo and pre-existing ITP with exacerbation of thrombocytopenia after vaccination. As a pre-existing ITP cohort, 49 consecutive patients who had previously been diagnosed with ITP and had received two doses of a mRNA-based COVID-19 vaccine, either BNT162b2 or mRNA-1273, were identified at Aiiku Hospital between 1 June 2021 and 31 March 2022. The diagnosis and the response criteria of ITP were defined according to International Consensus Guidelines.9 In patients with pre-existing ITP, ‘exacerbation of ITP’ was defined as previously reported.4 Patients with pre-existing ITP with exacerbation of thrombocytopenia within 30 days of the previous vaccination were considered as patients with post-vaccine ITP exacerbation. Apart from this cohort, we had two additional patients with de novo ITP following COVID-19 vaccination. Anti-SARS-CoV-2 spike (S) antibodies were measured at 3 months ± 2 weeks, 6 months ± 4 weeks and 9 months ± 4 weeks after the second vaccine dose as previously described.10 Considering the mean age of the patients with ITP, we recruited healthcare workers aged ≥55 years who had received two doses of BNT162b2 vaccine as healthy controls (HCs) (n = 28). There was no significant difference in age between the patients with ITP and HCs (mean [SD] 66.6 [7.2] vs. 60.2 [4.4] years; p = 0.060). Individuals with a known history of COVID-19 were excluded from both cohorts of patients and HCs. Of the 49 consecutive patients with pre-existing ITP, three patients (6.1%) showed exacerbation of ITP after COVID-19 vaccination (Table 1). One patient (unique patient number [UPN] 1) had repeated thrombocytopenia after the second and third doses. Two additional patients with de novo ITP following COVID-19 vaccination were identified in the same period (Table 1). Totally, four cases of exacerbation of ITP in three patients with pre-existing ITP and two cases of de novo ITP were identified as cases of ITP after COVID-19 vaccination. All except one of the patients required prompt treatment and all rescue treatments included corticosteroids. All of the treated patients responded and were on active treatment on the day of the data cut-off or last observation. Seroconversion rates after vaccination for both patients with post-vaccine ITP exacerbation and HCs were 100%. However, the antibody titres in patients with post-vaccine ITP exacerbation treated with corticosteroids were significantly lower than those in HCs at both 3 months (median [interquartile range, IQR] 153.0 [77.9–180.5] vs. 945.0 [402.5–1358.0] u/ml, p < 0.05) and 6 months (median [IQR] 66.9 [33.8–71.9] vs. 582.5 [240.5–1033.3] u/ml, p < 0.01) after vaccination (Figure 1A,B). On the other hand, in one patient with post-vaccine ITP exacerbation who did not receive rescue treatment (UPN5), the antibody titre at 6 months after vaccination (1232.0 u/ml) was comparable to that in HCs (median: 582.5 u/ml). Furthermore, in a previously healthy individual who developed ITP immediately after the first dose (UPN4), the antibody titre at 3 months was positive but was relatively low (2.7 u/ml) and subsequently became seronegative. In this patient, high-dose dexamethasone therapy followed by prednisolone was started immediately after the onset of ITP. It was recently reported that active therapy with corticosteroids reduced seroconversion rates and antibody titres after COVID-19 vaccination in patients with autoimmune cytopenias including ITP and in patients with haematological disease in the setting of post-allogenic stem cell transplantation.8, 11 In our study, although the number of cases is too small, treatment with corticosteroids may reduce the vaccine response in patients with post-vaccine ITP exacerbation. Strict measures for prevention of infection such as social-distancing practices might be recommended in patients with post-vaccine ITP exacerbation who receive corticosteroids treatment. On the other hand, the seroconversion rate after a single-dose of vaccine was shown to be lower than that after two doses of vaccine in immunocompromised patients.12, 13 Therefore, single-dose vaccination may also have contributed to the lower antibody titres in patient UPN4. A third dose of mRNA vaccine was reported to improve humoral immunity against SARS-CoV-2 and to be associated with seroconversion even in immunocompromised patients.12, 14 In our study, two patients developed ITP after the third dose (UPN1 and UPN3). These patients showed a marked increase of antibody titres after the third dose and rescue treatments were successful. On the other hand, another patient (UPN5) who developed de novo ITP after the second dose showed a marked increase of the antibody titre without developing ITP after the third dose. Based on very limited studies4, 6 and our results, it is recommended that patients with ITP should undergo at least the initial vaccination and that subsequent vaccination should be considered more carefully in patients who developed ITP after COVID-19 vaccination. There is still not enough evidence to inform the optimal management of a patient presenting with new or relapsed ITP during the COVID-19 pandemic.15 Depending on the situation, the use of thrombopoietin receptor agonists and intravenous immunoglobulin may be considered.15 Other immunosuppressive treatments, including rituximab, may reduce vaccine response, as may corticosteroids. In conclusion, careful monitoring of the platelet count after vaccination should be performed for patients with pre-existing ITP. In patients with post-vaccine ITP exacerbation, standard treatment with corticosteroids could abrogate the chance of acquiring anti-SARS-CoV-2 antibody. Akio Mori designed the study, analysed the data and wrote the manuscript. Masahiro Onozawa and Takanori Teshima revised and approved the manuscript. Mirei Kobayashi, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Makoto Saito and Masanobu Morioka performed recruitment and treatment of patients and provided critique to the manuscript. Haruna Muraki performed experiments and provided critique to the manuscript. Takeshi Kondo designed and supervised the study and approved the manuscript. All authors read and approved the final manuscript. The authors would like to thank the nursing staff and medical staff at Aiiku Hospital who looked after the patients, with special thanks to Ms Yuko Fujimaki, the nursing manager and Mr Masayuki Kudo, the Vice General Manager. We also thank Ms Kaori Shin at Aiiku Hospital for her work in data entry and management. The authors declare that they have no conflict of interest. The datasets generated and/or analysed during the present study are available from the corresponding author upon reasonable request. This study was part of a prospective observation study (UMIN000045267) and it was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the Institutional Review Board of Aiiku Hospital. Written informed consent was obtained from all individuals included in the study." @default.
• W4295431110 created "2022-09-14" @default.
• W4295431110 creator A5003763910 @default.
• W4295431110 creator A5011751372 @default.
• W4295431110 creator A5019384256 @default.
• W4295431110 creator A5025440917 @default.
• W4295431110 creator A5039515152 @default.
• W4295431110 creator A5041455800 @default.
• W4295431110 creator A5049775425 @default.
• W4295431110 creator A5053000890 @default.
• W4295431110 creator A5064182775 @default.
• W4295431110 creator A5069365250 @default.
• W4295431110 creator A5071956206 @default.
• W4295431110 creator A5072978730 @default.
• W4295431110 date "2022-09-12" @default.
• W4295431110 modified "2023-10-16" @default.
• W4295431110 title "Humoral response to <scp>mRNA</scp>‐based <scp>COVID</scp>‐19 vaccine in patients with de novo and pre‐existing <scp>immune thrombocytopenia</scp> with exacerbation of thrombocytopenia after vaccination" @default.
• W4295431110 cites W1984073642 @default.
• W4295431110 cites W3021302733 @default.
• W4295431110 cites W3111255098 @default.
• W4295431110 cites W3131011903 @default.
• W4295431110 cites W3157453497 @default.
• W4295431110 cites W3165147852 @default.
• W4295431110 cites W3197470157 @default.
• W4295431110 cites W3202007017 @default.
• W4295431110 cites W3204300787 @default.
• W4295431110 cites W4205483821 @default.
• W4295431110 cites W4206946734 @default.
• W4295431110 cites W4214519011 @default.
• W4295431110 cites W4280512248 @default.
• W4295431110 doi "https://doi.org/10.1111/bjh.18447" @default.
• W4295431110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36096497" @default.
• W4295431110 hasPublicationYear "2022" @default.
• W4295431110 type Work @default.
• W4295431110 citedByCount "4" @default.
• W4295431110 countsByYear W42954311102022 @default.
• W4295431110 countsByYear W42954311102023 @default.
• W4295431110 crossrefType "journal-article" @default.
• W4295431110 hasAuthorship W4295431110A5003763910 @default.
• W4295431110 hasAuthorship W4295431110A5011751372 @default.
• W4295431110 hasAuthorship W4295431110A5019384256 @default.
• W4295431110 hasAuthorship W4295431110A5025440917 @default.
• W4295431110 hasAuthorship W4295431110A5039515152 @default.
• W4295431110 hasAuthorship W4295431110A5041455800 @default.
• W4295431110 hasAuthorship W4295431110A5049775425 @default.
• W4295431110 hasAuthorship W4295431110A5053000890 @default.
• W4295431110 hasAuthorship W4295431110A5064182775 @default.
• W4295431110 hasAuthorship W4295431110A5069365250 @default.
• W4295431110 hasAuthorship W4295431110A5071956206 @default.
• W4295431110 hasAuthorship W4295431110A5072978730 @default.
• W4295431110 hasBestOaLocation W42954311102 @default.
• W4295431110 hasConcept C159047783 @default.
• W4295431110 hasConcept C203014093 @default.
• W4295431110 hasConcept C22070199 @default.
• W4295431110 hasConcept C2777014857 @default.
• W4295431110 hasConcept C71924100 @default.
• W4295431110 hasConcept C8891405 @default.
• W4295431110 hasConceptScore W4295431110C159047783 @default.
• W4295431110 hasConceptScore W4295431110C203014093 @default.
• W4295431110 hasConceptScore W4295431110C22070199 @default.
• W4295431110 hasConceptScore W4295431110C2777014857 @default.
• W4295431110 hasConceptScore W4295431110C71924100 @default.
• W4295431110 hasConceptScore W4295431110C8891405 @default.
• W4295431110 hasIssue "4" @default.
• W4295431110 hasLocation W42954311101 @default.
• W4295431110 hasLocation W42954311102 @default.
• W4295431110 hasLocation W42954311103 @default.
• W4295431110 hasOpenAccess W4295431110 @default.
• W4295431110 hasPrimaryLocation W42954311101 @default.
• W4295431110 hasRelatedWork W1992577796 @default.
• W4295431110 hasRelatedWork W2110265450 @default.
• W4295431110 hasRelatedWork W2130829219 @default.
• W4295431110 hasRelatedWork W2156169457 @default.
• W4295431110 hasRelatedWork W2553873465 @default.
• W4295431110 hasRelatedWork W2801381949 @default.
• W4295431110 hasRelatedWork W2952884403 @default.
• W4295431110 hasRelatedWork W4309103225 @default.
• W4295431110 hasRelatedWork W4311699418 @default.
• W4295431110 hasRelatedWork W2130939671 @default.
• W4295431110 hasVolume "199" @default.
• W4295431110 isParatext "false" @default.
• W4295431110 isRetracted "false" @default.
• W4295431110 workType "article" @default.